Medicine and Dentistry
Myelofibrosis
100%
Combination Therapy
71%
Patient
71%
Diseases
42%
Splenomegaly
28%
Polycythemia vera
28%
Essential Thrombocythaemia
28%
Prematurity
14%
Toxicity
14%
Pathophysiology
14%
Cytopenia
14%
Development
14%
Anemia
14%
Introspection
14%
Symptom
14%
Ruxolitinib
14%
Drug
14%
Chemotherapeutic Agent
14%
Constitutional Symptoms
14%
Myeloid metaplasia
14%
Allogeneic Stem Cell Transplantation
14%
Janus Kinase 2 Inhibitor
14%
Fedratinib
14%
Mechanism of Action
14%
Janus Kinase
14%
Pharmacology, Toxicology and Pharmaceutical Science
Myelofibrosis
100%
Diseases
42%
Splenomegaly
28%
Thrombocythemia
28%
Polycythemia vera
28%
Toxicity
14%
Prematurity
14%
Cytopenia
14%
Pathophysiology
14%
Anemia
14%
Drug
14%
Ruxolitinib
14%
Janus Kinase 2 Inhibitor
14%
Myeloid metaplasia
14%
Fedratinib
14%
Myeloproliferative Neoplasm
14%
Death
14%
Symptom
14%